trust fall lower estim price maintain ow rate
invest summari lower sale ebitda ep estim
well price target reduc
ebitda guidanc factset
also lower ebitda think factset estim
high recent lower number well
price target clearli enough said maintain
ow rate still see lot valu unlock even though
execut gone anticip decreas price target driven
downward earn revis multipl contract
 concern remain regard growth valuat although stock
re-rat investor still concern downsid risk
ebitda guidanc earn still back-end load
furthermor commentari today reduc earn visibl
compani unclear may return growth final
consider debat regard right ev/ebitda multipl
stock light news today
 made follow assumpt model impact
cost cut affect much estim sg
 expens line factset major
restructur mileston expect achiev
full benefit longer expect sale nuvar
even get approv end impact like
small year nuvar expect good margin expect
margin qoq given lower volum per press releas
think price volum hit competit pressur buy
group could neg read-through gener compani
teva expect ebitda
come ebitda
 import point consid like revis remain
guidanc report result compani
comment receiv nuvar teva confirm expect
nuvar unchang seen bounce-back shortag
foxbusi note nv nc begin sell emerg
allergi medicin partner adami nc pharmaci amid shortag
compet product epipen report sale
epinephrin per debt coven
light concern point
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price
target gener drug price could declin custom consolid creat
greater leverag buy consortium extract price concess gener
compani gener consolid may make harder amneal compet small mid-
size gener compani need consolid stay competit market custom
increas buy power amneal competitor get bigger amneal stay
could make hard amneal compet industri gener competit
rytari could drive downward earn revis estim consensu expect
exhibit cantor estim versu manag guidanc includ updat ebitda guidanc rest guidanc updat yet
amnealcantor mm except per share amount guidancemidpointestimateadjust gross margin sg effect tax share cantor fitzgerald research compani announc plan restructur oper intend reduc cost optim organiz manufactur pursuant restructur plan expect reduc headcount end close manufactur facil locat hauppaug ny packag facil locat east hanov result restructur plan estim incur pre-tax restructur charg cash relat sever benefit cash non-cash expendituresassoci restructur plan includ decommiss dismantl cost third parti cost impact facil estim expect restructur substanti complet end estim subject number assumpt may also incur addit cost current contemplateddu event may occur result connect restructur exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
amneal pharmaceut inc result busi combin impax laboratori inc amneal pharmaceut llc
effect may amneal technology-bas specialti pharmaceut compani focus drug deliveri formul amneal
oper includ gener busi target high-valu solid oral altern dosag form abbrevi new drug applic
anda brand busi focus develop intern central nervou system product
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
cantor fitzgerald and/or affili market maker
cantor fitzgerald and/or affili market maker inc
cantor fitzgerald and/or affili market maker teva ind ltd
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
materi approv distribut unit kingdom cantor fitzgerald europ cfe cfe authoris regul
conduct author fca believ inform materi upon inform base accur except
oblig rule fca guarante accuraci materi intend use elig counterparti profession
client fall within articl servic market act promot order gener invest
public none invest invest servic mention describ herein avail person particular
avail retail client defin rule fca
disclosur canadian institut investor
research report prepar analyst cantor fitzgerald co cantor fitzgerald canada corpor result report
prepar subject canadian disclosur requir cantor fitzgerald canada may distribut research report prepar affili
financi instrument discuss report may suitabl investor investor must make invest decis base
specif invest object past perform taken indic guarante futur perform price valu
incom financi instrument featur report rise well fall affect chang econom financi polit
factor financi instrument denomin currenc investor currenc chang exchang rate may advers affect price
valu incom deriv financi instrument investor effect assum currenc risk addit investor secur
adr whose valu affect currenc home market underli secur effect assum currenc risk
rate price target histori inc
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
rate price target histori
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
rate price target histori mylan inc
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
rate price target histori teva pharmaceut ind ltd teva
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
distribut ratings/invest bank servic ib
addit inform avail request copyright cantor fitzgerald
head healthcar research
